{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:04:00Z","timestamp":1791810240196,"version":"4.3.4"},"reference-count":28,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"14","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2021,12,21]]},"DOI":"10.1167\/tvst.10.14.23","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:42:41Z","timestamp":1640086961000},"page":"23","source":"Crossref","is-referenced-by-count":23,"title":["A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration"],"prefix":"10.1167","volume":"10","author":[{"given":"Wen-Chia","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ching","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hsien","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Jen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Chan","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Drug Delivery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Mu","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-En","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Preclinical Drug Discovery Technology, Target Drug and Delivery Technology Division, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, 300 Taiwan, Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"issue":"13","key":"bib1","first-page":"5616","article-title":"Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies.","volume":"58","author":"Zhang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"bib2","doi-asserted-by":"publisher","first-page":"e108196","DOI":"10.1371\/journal.pone.0108196","article-title":"Diabetes mellitus and risk of age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye (Lond)"},{"issue":"1","key":"bib4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000510330","article-title":"Efficacy of psychiatric treatment to treat a specific phobia of intravitreal injections in a patient with neovascular age-related macular degeneration","volume":"12","author":"Ozaki","year":"2021","journal-title":"Case Rep Ophthalmol"},{"issue":"4","key":"bib5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4274\/tjo","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"issue":"2","key":"bib6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/bcp.v85.2","article-title":"The developing regorafenib eye drops for neovascular age-related macular degeneration (DREAM) study: an open-label phase II trial","volume":"85","author":"Joussen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"bib7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"bib8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.exer.2016.02.010","article-title":"Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo Models","volume":"145","author":"Giddabasappa","year":"2016","journal-title":"Exp. Eye Res"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"101462","DOI":"10.1016\/j.jddst.2019.101462","article-title":"Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their ?-cyclodextrin solubilization","volume":"55","author":"Praphanwittaya","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"bib11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"issue":"10","key":"bib12","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1021\/mp500332m","article-title":"On the barrier properties of the cornea: A microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein","volume":"11","author":"Mun","year":"2014","journal-title":"Mol Pharm"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"101341","DOI":"10.1016\/j.jddst.2019.101341","article-title":"A corneal-penetrating eye drop formulation for enhanced therapeutic efficacy of soft corticosteroids against anterior uveitis","volume":"54","author":"Huang","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"issue":"12","key":"bib14","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1167\/iovs.07-0731","article-title":"The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits","volume":"48","author":"Ameri","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.exer.2018.05.027","article-title":"A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies","volume":"174","author":"Li","year":"2018","journal-title":"Exp Eye Res"},{"issue":"12","key":"bib16","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1167\/iovs.06-0156","article-title":"A novel imaging technique for experimental choroidal neovascularization","volume":"47","author":"Campos","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"bib17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"bib18","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1002\/jps.23077","article-title":"Cyclodextrins as functional excipients: methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"J Pharm Sci"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jconrel.2018.05.034","article-title":"Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells","volume":"283","author":"Rimpel\u00e4","year":"2018","journal-title":"J Control Release"},{"issue":"106","key":"bib21","first-page":"53502","article-title":"A mouse model for laser-induced choroidal neovascularization","author":"Shah","year":"2015","journal-title":"J Vis Exp"},{"issue":"1-3","key":"bib22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2011.05.016","article-title":"Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats","volume":"666","author":"Yafai","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"bib24","doi-asserted-by":"publisher","first-page":"e00545","DOI":"10.1002\/prp2.v7.6","article-title":"Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys","volume":"7","author":"Horita","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.exer.2012.03.004","article-title":"Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes","volume":"98","author":"Durairaj","year":"2012","journal-title":"Exp Eye Res"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","article-title":"Implications of melanin binding in ocular drug delivery","volume":"126","author":"Rimpel\u00e4","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"bib27","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1021\/acs.molpharmaceut.9b00157","article-title":"Influence of melanin characteristics on drug binding properties","volume":"16","author":"Jakubiak","year":"2019","journal-title":"Mol Pharm"},{"issue":"4","key":"bib28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/acs.molpharmaceut.5b00783","article-title":"Interpretation of ocular melanin drug binding assays. Alternatives to the model of multiple classes of independent sites","volume":"13","author":"Manzanares","year":"2016","journal-title":"Mol Pharm"},{"key":"bib20","article-title":"CHMP assessment report for Inlyta","author":"EMA.Europa.eu","year":"2015"},{"key":"bib23","article-title":"Topically administered regorafenib eye drops inhibit grade IV lesions in the non-human primate laser CNV model","volume-title":"Presented at: ARVO 2015 Annual Meeting, 3\u20137 May 2015","author":"Boettger"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2778174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:42:46Z","timestamp":1640086966000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2778174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.10.14.23","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}